Citryll

biotech · Oss, NL

Biotech developing antibody therapies targeting Neutrophil Extracellular Traps.

Founders

Helmuth van Es (Netherlands · ♂) — A serial Dutch biotech entrepreneur who co-founded multiple drug companies, he spun Citryll out of ModiQuest's tACPA patents in 2015 to develop antibodies targeting neutrophil extracellular traps, serving as CEO.
Renato Chirivi (Italy · ♂) — An immunology researcher and co-inventor of the tACPA antibody technology at ModiQuest, he co-founded Citryll as CSO to turn his NET-targeting science into therapies.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Dec 2024	Series B Dutch biotech Citryll closed an oversubscribed EUR 85M Series B co-led by Johnson & Johnson, Forbion and Novartis Venture Fund to advance its anti-inflammatory antibody CIT-013.	$90M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.